Picture of iRhythm Holdings logo

IRTC — iRhythm Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

iRhythm Q2 revenue beats estimates on sustained volume demand, lifts FY guidance

iRhythm Q2 revenue beats estimates on sustained volume demand, lifts FY guidance


Overview

  • Digital health care firm's Q2 revenue rose 20% yr/yr, beating analyst expectations

  • Adjusted net income turned positive from a loss a year ago

  • Company to acquire Vital Connect for $287.5 mln to expand cardiac monitoring platform


Outlook

  • iRhythm raised 2026 revenue guidance to $880 mln-$890 mln

  • Company expects 2026 adjusted EBITDA margin of 13.0%-14.0%

  • Company anticipates continued volume-led growth and margin expansion in 2026


Result Drivers

  • VOLUME-LED GROWTH - Revenue increase was driven primarily by sustained volume demand across the customer base and strength in core business and new channels

  • OPERATIONAL EFFICIENCIES - Gross margin improvement was attributed to operational efficiencies, product mix, and scale benefits from higher volumes

  • DISCIPLINED COST MANAGEMENT - Adjusted operating expenses were flat year-over-year, reflecting a disciplined approach to investment while funding key growth initiatives


Company press release: ID:nGNX3H9xqQ


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$224.20 mln

$219.32 mln (15 Analysts)

Q2 Adjusted Net Income

$19.30 mln

Q2 Net Loss

$400,000

Q2 Gross Margin

72.80%

Q2 Gross Profit

$163.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for iRhythm Holdings, Inc is $180.00, about 44.6% above its August 5 closing price of $124.50

  • The stock recently traded at 190 times the next 12-month earnings vs. a P/E of 1,692 three months ago


Reuters Recommended Reads

  • Aug 6 - Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength

  • Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook

  • Aug 5 - Grail Q2 revenue rises 26%, net loss narrows 3%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on iRhythm Holdings

See all news